TM3 Therapeutics
About TM3 Therapeutics
TM3 Therapeutics is focused on novel treatments for neurodegenerative and metabolic diseases by developing unique metabolite replacement therapies. Our goal is to improve survival outcomes and quality of life of patients with rare, genetic neurological diseases that have limited or no treatment options. Our clinical development program specifically targets the coenzyme A biosynthetic pathway, whose malfunction leads to impaired quality of life, progressive loss of function and significantly reduced life expectancy. Our vision is to work together with key opinion leaders, researchers and clinicians to expedite the development of new therapeutics to treat diseases with significant unmet medical need. Based in Leiden, The Netherlands, the company was founded in 2017.YEAR FOUNDED:
2017
LEADERSHIP:
CEO: Enej Kuscer
2 articles about TM3 Therapeutics
-
TM3 Therapeutics Appoints Peter Van Vlasselaer as Chairman of the Board
11/29/2017
Dr. Van Vlasselaer is currently Chief Executive Officer of ARMO Biosciences.
-
TM3 Therapeutics Debuts With Publication Of In Vivo Proof Of Concept Data For Lead Compound In Treating Pantothenate Kinase-Associated Neurodegeneration
9/13/2017